Literature DB >> 19235263

Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data.

Brian L Egleston1, Yu-Ning Wong.   

Abstract

Having substantial missing data is a common problem in administrative and cancer registry data. We propose a sensitivity analysis to evaluate the impact of a covariate that is potentially missing not at random in survival analyses using Weibull proportional hazards regressions. We apply the method to an investigation of the impact of missing grade on post-surgical mortality outcomes in individuals with metastatic kidney cancer. Data came from the Surveillance Epidemiology and End Results (SEER) registry which provides population-based information on those undergoing cytoreductive nephrectomy. Tumor grade is an important component of risk stratification for patients with both localized and metastatic kidney cancer. Many individuals in SEER with metastatic kidney cancer are missing tumor grade information. We found that surgery was protective, but that the magnitude of the effect depended on assumptions about the relationship of grade with missingness. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19235263      PMCID: PMC2741403          DOI: 10.1002/sim.3557

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  15 in total

1.  Augmented inverse probability weighted estimator for Cox missing covariate regression.

Authors:  C Y Wang; H Y Chen
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

2.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  A sensitivity analysis for nonrandomly missing categorical data arising from a national health disability survey.

Authors:  Stuart G Baker; Chia-Wen Ko; Barry I Graubard
Journal:  Biostatistics       Date:  2003-01       Impact factor: 5.899

4.  Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.

Authors:  Ronald J Halbert; Robert A Figlin; Michael B Atkins; Myriam Bernal; Thomas E Hutson; Robert G Uzzo; Ronald M Bukowski; Khuda Dad Khan; Christopher G Wood; Robert W Dubois
Journal:  Cancer       Date:  2006-11-15       Impact factor: 6.860

5.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

6.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

7.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Authors:  R J Motzer; M Mazumdar; J Bacik; W Berg; A Amsterdam; J Ferrara
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

8.  Survival associated with treatment vs observation of localized prostate cancer in elderly men.

Authors:  Yu-Ning Wong; Nandita Mitra; Gary Hudes; Russell Localio; J Sanford Schwartz; Fei Wan; Chantal Montagnet; Katrina Armstrong
Journal:  JAMA       Date:  2006-12-13       Impact factor: 56.272

9.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

10.  Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.

Authors:  Jean-Jacques Patard; Hyung L Kim; John S Lam; Frederick J Dorey; Allan J Pantuck; Amnon Zisman; Vincenzo Ficarra; Ken-Ryu Han; Luca Cindolo; Alexandre De La Taille; Jacques Tostain; Walter Artibani; Colin P Dinney; Christopher G Wood; David A Swanson; Claude C Abbou; Bernard Lobel; Peter F A Mulders; Dominique K Chopin; Robert A Figlin; Arie S Belldegrun
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

View more
  3 in total

1.  Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database.

Authors:  Shiori Hasegawa; Hiroaki Ikesue; Riko Satake; Misaki Inoue; Yu Yoshida; Mizuki Tanaka; Kiyoka Matsumoto; Wataru Wakabayashi; Keita Oura; Nobuyuki Muroi; Tohru Hashida; Kazuhiro Iguchi; Mitsuhiro Nakamura
Journal:  Drugs Real World Outcomes       Date:  2022-08-06

2.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

3.  Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival.

Authors:  Daniel X Yang; Rohan Khera; Joseph A Miccio; Vikram Jairam; Enoch Chang; James B Yu; Henry S Park; Harlan M Krumholz; Sanjay Aneja
Journal:  JAMA Netw Open       Date:  2021-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.